company background image
0LW logo

Neovacs DB:0LW Stock Report

Last Price

€5.00

Market Cap

€703.4k

7D

0%

1Y

-100.0%

Updated

04 Feb, 2024

Data

Company Financials

0LW Stock Overview

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.

0LW fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Neovacs S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neovacs
Historical stock prices
Current Share Price€5.00
52 Week High€160,000.00
52 Week Low€5.00
Beta0.58
1 Month Change0%
3 Month Change0%
1 Year Change-100.00%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

0LWDE BiotechsDE Market
7D0%2.1%1.9%
1Y-100.0%37.0%7.3%

Return vs Industry: 0LW underperformed the German Biotechs industry which returned -23.7% over the past year.

Return vs Market: 0LW underperformed the German Market which returned -2.6% over the past year.

Price Volatility

Is 0LW's price volatile compared to industry and market?
0LW volatility
0LW Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 0LW has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0LW's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199323Hugo Brugierehttps://www.neovacs.com

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies.

Neovacs S.A. Fundamentals Summary

How do Neovacs's earnings and revenue compare to its market cap?
0LW fundamental statistics
Market cap€703.37k
Earnings (TTM)-€5.00m
Revenue (TTM)€53.48k

13.2x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0LW income statement (TTM)
Revenue€53.48k
Cost of Revenue€3.63m
Gross Profit-€3.58m
Other Expenses€1.42m
Earnings-€5.00m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-14.21
Gross Margin-6,686.05%
Net Profit Margin-9,343.60%
Debt/Equity Ratio3.0%

How did 0LW perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.